支气管动脉灌注紫杉醇联合全身化疗治疗晚期非小细胞肺癌  

Efficacy of bronchial arterial infusion of paclitaxel combined with systemic chemotherapy for patients with advanced non-small cell cancer

作　　者：张华[1] 罗鹏飞[1] 张良明[1] 邵培坚[1] 周泽健[1] 郑伟华[1] 

机构地区：[1]广东省人民医院肿瘤科,510080

出　　处：《介入放射学杂志》2001年第5期283-285,共3页Journal of Interventional Radiology

摘　　要：目的　观察选择性经支气管动脉灌注紫杉醇 (泰素 )及卡铂并联合紫杉醇全身化疗治疗晚期非小细胞肺癌 (NSCLC)的疗效及不良反应。方法　对 5 7例晚期NSCLC患者经支气管动脉注入紫杉醇和卡铂 ,同时予紫杉醇全身化疗 ,每例均完成 2～ 3周期后评价其疗效及不良反应。结果　 5 7例中完全缓解 (CR) 6例 ,部分缓解 (PR) 2 8例 ,总有效率 5 9.6 %。主要不良反应为骨髓抑制、胃肠道反应、脱发等 ,不良反应多为Ⅰ～Ⅱ度。结论　经支气管动脉灌注紫杉醇和卡铂并联合紫杉醇全身化疗是治疗晚期非小细胞肺癌的一种有疗效好。Objective To evaluate the efficacy and toxicity of bronchial arterial infusion (BAI) combined with systemic administration of paclitaxel (Taxol) in the treatment of patients with advanced non small cell cancer (NSCLC).Methods Fifty seven patients with NSCLC were received paclitaxel and carboplatin through the bronchial artery and follow by systemic administration of paclitaxel for 2～3 cycles. The positive response and adverse effects were assessed. Results In 57 patients, complete response (CR) were obtained in 6 and partial response (PR) in 28 cases, with overall response rate (RR) of 59.6%. The main toxicity included mild myelosuppression, gastrointestinal effects, and alopecia.Conclusions The combination of BAI of paclitaxel and systemic chemotherapy is highly effective for advanced NSCLC, and causes mild adverse effects.

关 键 词：支气管动脉灌注 紫杉醇 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]